Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

Annotations already mark readOnly and non-destructive; the description adds meaningful behavior beyond that: it sources from openFDA, returns brand/generic and warning data, flags shared generics, and includes price and disclaimers. No annotation contradiction.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is dense and informative, with purpose, scope, source, exclusions, and price in a compact parcel. The opening 'Drug safety compare (bundle)' repeats the tool/title, but only minor redundancy.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

There is no output schema, so the description does the necessary work of explaining what the caller gets: side-by-side label safety, indications/warnings per drug, and shared-generic flag. It also covers source, cost, and exclusions, making it sufficiently complete for a simple two-parameter read-only tool.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Schema description coverage is 100% (a and b are both 'first/second drug (brand or generic)'), so the description adds little beyond the schema. It reinforces that both drugs are accepted as brand or generic, but does not add formatting, era, or disambiguation details.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Does the description clearly state what the tool does and how it differs from similar tools?

Clearly states it compares FDA label safety for two drugs side-by-side and lists the specific outputs (brand/generic identity, indications, warnings, shared-generic flag). This distinguishes it from single-drug or other health tools in the sibling list, even without explicitly naming them.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Does the description explain when to use this tool, when not to, or what alternatives exist?

The description explicitly excludes drug-interaction analysis and medical advice, which helps an agent avoid misusing it. It implies use for side-by-side safety comparison rather than single-label lookups, though it does not name an alternative sibling like fda_drug_label.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.